Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection

NCT06508138 · clinicaltrials.gov ↗

PHASE1

Phase

ENROLLING_BY_INVITATION

Status

24

Enrollment

OTHER

Sponsor class

Conditions

HPV 16 Infection
HPV-Related Carcinoma
Recurrence
Metastatic Cancer

Interventions

BIOLOGICAL: pNGVL4a-Sig/E7(detox)/HSP70 plasmid DNA; TA-HPV vaccinia virus

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]
[object Object]